Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience.

Bourien H, Palard X, Rolland Y, Le Du F, Beuzit L, Uguen T, Le Sourd S, Pracht M, Manceau V, Lièvre A, Boudjema K, Garin E, Edeline J.

Eur J Nucl Med Mol Imaging. 2018 Oct 29. doi: 10.1007/s00259-018-4199-5. [Epub ahead of print]

PMID:
30374530
2.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

PMID:
30054279
3.

Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authors' reply.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 Sep;50(9):974-975. doi: 10.1016/j.dld.2018.06.014. Epub 2018 Jun 28. No abstract available.

PMID:
30005959
4.

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.

Br J Cancer. 2018 Aug;119(3):387. doi: 10.1038/s41416-018-0130-x.

PMID:
29899390
5.

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences.

Cacheux W, Tsantoulis P, Briaux A, Vacher S, Mariani P, Richard-Molard M, Buecher B, Richon S, Jeannot E, Lazartigues J, Rouleau E, Mariani O, El Alam E, Cros J, Roman-Roman S, Mitry E, Girard E, Dangles-Marie V, Lièvre A, Bièche I.

Cancer Med. 2018 May 26. doi: 10.1002/cam4.1533. [Epub ahead of print]

6.

Immediate Effects of Thoracic Spine Thrust Manipulation on Neurodynamic Mobility.

Hartstein AJ, Lievre AJ, Grimes JK, Hale SA.

J Manipulative Physiol Ther. 2018 May;41(4):332-341. doi: 10.1016/j.jmpt.2017.10.006. Epub 2018 Apr 16.

PMID:
29669688
7.

Prognostic value of serum CYFRA 21-1 1 in patients with anal canal squamous cell carcinoma treated with radio(chemo)therapy.

Gauthé M, Richard-Molard M, Rigault E, Buecher B, Mariani P, Bellet D, Cacheux W, Lièvre A.

BMC Cancer. 2018 Apr 13;18(1):417. doi: 10.1186/s12885-018-4335-4.

8.

A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy.

Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, Boudjema K, Lievre A, Mesbah H, Haumont LA, Lenoir L, Brun V, Uguen T, Edeline J, Garin E.

Eur J Nucl Med Mol Imaging. 2018 Sep;45(10):1731-1741. doi: 10.1007/s00259-018-3990-7. Epub 2018 Mar 20.

PMID:
29560519
9.

[Metastatic colorectal cancer: To stop or not to stop?]

Artru P, Bennouna J, Lievre A, Ducreux M, Lledo G.

Bull Cancer. 2018 Apr;105(4):408-414. doi: 10.1016/j.bulcan.2017.12.010. Epub 2018 Feb 22. Review. French.

PMID:
29477654
10.

Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.

Cacheux W, Dangles-Marie V, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Farkhondeh F, Mariani O, Rio-Frio T, Roman-Roman S, Mitry E, Bieche I, Lièvre A.

Oncotarget. 2017 Dec 8;9(1):464-476. doi: 10.18632/oncotarget.23066. eCollection 2018 Jan 2.

11.

RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014.

Lièvre A, Merlin JL, Sabourin JC, Artru P, Tong S, Libert L, Audhuy F, Gicquel C, Moureau-Zabotto L, Ossendza RA, Laurent-Puig P, Ducreux M.

Dig Liver Dis. 2018 May;50(5):507-512. doi: 10.1016/j.dld.2017.12.029. Epub 2018 Jan 8.

12.

Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.

Walter T, Malka D, Hentic O, Lombard-Bohas C, Le Malicot K, Smith D, Ferru A, Assenat E, Cadiot G, Lievre A, Kurtz JE, Dahan L, Dubreuil O, Hautefeuille V, Lepere C, Gangloff A, Elhajbi F, Coriat R, Roquin G, Bouarioua N, Granger V, Scoazec JY, Lepage C.

Dig Liver Dis. 2018 Feb;50(2):195-198. doi: 10.1016/j.dld.2017.11.020. Epub 2017 Dec 6.

PMID:
29258812
13.

Low participation in organized colorectal cancer screening in France: underlying ethical issues.

Moutel G, Duchange N, Lièvre A, Orgerie MB, Jullian O, Sancho-Garnier H, Darquy S.

Eur J Cancer Prev. 2017 Nov 24. doi: 10.1097/CEJ.0000000000000417. [Epub ahead of print]

14.

Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.

Lièvre A, Ouine B, Canet J, Cartier A, Amar Y, Cacheux W, Mariani O, Guimbaud R, Selves J, Lecomte T, Guyetant S, Bieche I, Berger F, de Koning L.

Br J Cancer. 2017 Dec 5;117(12):1819-1827. doi: 10.1038/bjc.2017.353. Epub 2017 Oct 12. Erratum in: Br J Cancer. 2018 Aug;119(3):387.

15.

Incidental colorectal focal 18 F-FDG uptake: a novel indication for colonoscopy.

Rigault E, Lenoir L, Bouguen G, Pagenault M, Lièvre A, Garin E, Siproudhis L, Bretagne JF.

Endosc Int Open. 2017 Sep;5(9):E924-E930. doi: 10.1055/s-0043-116384. Epub 2017 Sep 13.

16.

Fecal immunological blood test is more appealing than the guaiac-based test for colorectal cancer screening.

Le Pimpec F, Moutel G, Piette C, Lièvre A, Bretagne JF.

Dig Liver Dis. 2017 Nov;49(11):1267-1272. doi: 10.1016/j.dld.2017.08.018. Epub 2017 Aug 10.

PMID:
28867474
17.

Addressing low participant in colorectal cancer screening: Respect for individual freedom versus the community good.

Moutel G, Duchange N, Lièvre A, Darquy S.

Dig Liver Dis. 2017 Sep;49(9):1064-1065. doi: 10.1016/j.dld.2017.05.023. Epub 2017 Jun 21. No abstract available.

PMID:
28647391
18.

Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.

Lepage C, Dahan L, Bouarioua N, Toumpanakis C, Legoux JL, Le Malicot K, Guimbaud R, Smith D, Tougeron D, Lievre A, Cadiot G, Di Fiore F, Bouhier-Leporrier K, Hentic O, Faroux R, Pavel M, Borbath I, Valle JW, Rinke A, Scoazec JY, Ducreux M, Walter T.

Dig Liver Dis. 2017 May;49(5):568-571. doi: 10.1016/j.dld.2017.02.004. Epub 2017 Mar 11.

PMID:
28292641
19.

Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.

Viaud J, Brac C, Artru P, Le Pabic E, Leconte B, Bodère A, Pracht M, Le Sourd S, Edeline J, Lièvre A.

Dig Liver Dis. 2017 Jun;49(6):692-696. doi: 10.1016/j.dld.2017.02.007. Epub 2017 Feb 14.

20.

Preoperative bevacizumab and surgery for colorectal liver metastases: a propensity score analysis.

Bergeat D, Rayar M, Mouchel Y, Merdrignac A, Meunier B, Lièvre A, Boudjema K, Sulpice L.

Langenbecks Arch Surg. 2017 Feb;402(1):57-67. doi: 10.1007/s00423-017-1551-3. Epub 2017 Jan 13.

PMID:
28084516

Supplemental Content

Loading ...
Support Center